References of "Fardellone, Patrice"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLong-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years.
Reginster, Jean-Yves ULg; Bruyère, Olivier ULg; Sawicki, A. et al

in BONE (2009), 45

OBJECTIVES: Strontium ranelate 2 g/day has proven efficacy against vertebral and nonvertebral fracture over 5 years in postmenopausal osteoporosis, though many women require longer-term treatment. This ... [more ▼]

OBJECTIVES: Strontium ranelate 2 g/day has proven efficacy against vertebral and nonvertebral fracture over 5 years in postmenopausal osteoporosis, though many women require longer-term treatment. This article describes the efficacy, safety, and tolerability of this agent over 8 years. METHODS: Postmenopausal osteoporotic women having participated in the 5-year efficacy trials SOTI and TROPOS were invited to enter a 3-year open-label extension study. The results presented here focus on patients who received strontium ranelate for 8 years. RESULTS: At the extension baseline, the population treated for 8 years (n=879; 79.1+/-5.6 years) had femoral neck T-score of -2.61+/-0.71. The cumulative incidences of new vertebral and nonvertebral fractures (13.7% and 12.0%, respectively) over years 6 to 8 were non-statistically different from the cumulative incidences in the first 3 years of the original studies (11.5% and 9.6%). Lumbar spine, femoral neck, and total hip bone mineral density (BMD) increased throughout the 8-year period. Annual relative change in BMD was significant at every visit, except the 8-year visit for femoral neck and total hip BMD. Strontium ranelate was safe and well tolerated over 8 years. CONCLUSIONS: Long-term treatment with strontium ranelate 2 g/day in postmenopausal osteoporotic women leads to continued increases in BMD at all sites. The data also provide some evidence for a sustained antifracture efficacy. [less ▲]

Detailed reference viewed: 93 (31 ULg)
Full Text
Peer Reviewed
See detailCorrélation entre l'augmentation de la densité minérale osseuse et la réduction du risque fracturaire lors d'un traitement par ranélate de strontium
Bruyère, Olivier ULg; Cormier, C.; Fardellone, Patrice et al

in Revue du Rhumatisme (2006, December), 73

Detailed reference viewed: 7 (4 ULg)
Full Text
Peer Reviewed
See detailA new treatment for the reduction of vertebral and non-vertebral fractures in post-menopausal women with osteoporosis
Reginster, Jean-Yves ULg; Brixen, Kim; Bianchi, Gerolamo et al

in Arthritis and Rheumatism (2004, September), 50(number 9 (suppl.)), 291

Detailed reference viewed: 19 (9 ULg)
Full Text
Peer Reviewed
See detailRapid and sustained anti-fracture efficacy of strontium ranelate in postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Sawicki, A.; Devogelaer, Jean-Pierre et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 584-5

Detailed reference viewed: 13 (0 ULg)